Utah People's Post

The Latest News from the Beehive State

Sunday, August 14, 2022
Log in
  • National News
    • Female Caseworker Killed & Doctor Shot in Philadelphia
  • State News
    • Car Chase Leads to Drug Arrest
  • Tech & Science
  • Health
    • How to Prepare For Ticks Season
    • Magical Weight Loss Bean Scam
  • Sports
  • Business
You are here: Home / Health / Incyte Drug Jakafi to Treat Polycythemia Vera (PV)

Incyte Drug Jakafi to Treat Polycythemia Vera (PV)

December 6, 2014 Posted by Editor

Jakafi

 

The Food and Drug Administration (FDA) has approved Incyte drug Jakafi to treat Polycythemia Vera in patients who have had an unsatisfactory response to or do not tolerate hydroxyurea.  This is the first time the FDA has approved a drug for PV.

Jakafi, a targeted kinase inhibitor manufactured by Incyte,  reportedly offers a salutary option for some people affected by this serious blood disorder, a type of myeloproliferative disease.

“The approval of Jakafi represents an important advance for patients with uncontrolled PV. For the first time we are able to provide these patients a treatment that has been shown to provide effective and consistent control of their blood counts and reduce spleen volume,”

Srdan Verstovsek, Professorat the Texas University,Leukemia Department said.

Polycythemia Vera is a serious condition, characterized as a myeloproliferative neoplasm (MPN). The condition usually presents with elevated red blood cell counts, which in turn, can lead to a high viscosity of the blood and an increased risk of clotting. Additionally, elevated white blood cell and platelet counts may be present. Many patients also eventually develop a larger spleen, a condition which can be painful and even disfiguring.

PV is not an “active” condition, but this doesn’t mean it is not dangerous. Fortunately it can be easily detected with a simple blood test, examining a high hemoglobin level.

Occurring at virtually any age, it mostly affects elderly people, with a median age at diagnosis of 60 years. Moreover, approximately 50 out of every 100,000 patients in the United States are suffering from this malignant or premalignant disorder. Out of these 50 patients, about one-quarter of all patients will experience drug resistance to or intolerance for hydroxyurea.

The FDA initially approved ruxolitinib as a treatment for patients with intermediate and high-risk myelofibrosis back in November 2011. This approval meant its contributing to the treatment of primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. In Myelofibrosis , Fibrosis occurs in bone marrow. It is a rare condition that replaces the ment of bone marrow by collagenous connective tissue fibres.

The most common side effects of Jakafi include: anemia, low platelet count, bruising, dizziness, headache.

Share this:

  • Tweet
  • Share on Tumblr
  • Email

Filed Under: Health Tagged With: chronic bone marrow disease, Incyte, Incyte drug Jakafi, Jakafi, myeloproliferative disease, Polycythemia Vera, PV

Woman working out at the gym

Just 23% of Americans Are Working Out Enough in Their Spare Time

June 29, 2018 By Amelia Donovan

Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

June 29, 2018 By Amelia Donovan

United Airlines airplane

Passenger Mysteriously Dies on United Airlines flight Bound for Boston

June 28, 2018 By Amelia Donovan

Breakfast sandwich

Here Are Some Foods No Nutritionist Would Ever Eat

June 27, 2018 By Amelia Donovan

Poppy flower

UN Warns of Surge in Opium-based Drugs and Cocaine Supply

June 27, 2018 By Amelia Donovan

U.S.-Canada border

French Jogger Detained 2 Weeks for Accidentally Crossing Border

June 26, 2018 By Amelia Donovan

Plus size model

Normalizing Plus Size Could Fuel Obesity Crisis (Study)

June 25, 2018 By Amelia Donovan

Giant manta ray

Unique Manta Ray Nursery Spotted off Texas Coast

June 23, 2018 By Amelia Donovan

The rainbow flag

WHO Scraps Transgenderism from List of Mental Illnesses

June 22, 2018 By Amelia Donovan

456 People Dead at U.K. Hospital after Taking too Many Painkillers

June 21, 2018 By Amelia Donovan

Kenyan girls dancing

Kenyans Facing Poor Nutrition as Supermarket Shopping Is on the Rise

June 20, 2018 By Amelia Donovan

Pages

  • About
  • Contact
  • Privacy Policy GDPR
  • Staff
  • Terms and Conditions

Recent Posts

  • Just 23% of Americans Are Working Out Enough in Their Spare Time
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)
  • Passenger Mysteriously Dies on United Airlines flight Bound for Boston
  • Here Are Some Foods No Nutritionist Would Ever Eat
  • UN Warns of Surge in Opium-based Drugs and Cocaine Supply
  • French Jogger Detained 2 Weeks for Accidentally Crossing Border
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

Related Articles

  • Woman working out at the gym

    Just 23% of Americans Are Working Out Enough in Their Spare Time

    Jun 29, 2018
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

    Jun 29, 2018
  • Breakfast sandwich

    Here Are Some Foods No Nutritionist Would Ever Eat

    Jun 27, 2018
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

    Jun 25, 2018
  • The rainbow flag

    WHO Scraps Transgenderism from List of Mental Illnesses

    Jun 22, 2018
  • 456 People Dead at U.K. Hospital after Taking too Many Painkillers

    Jun 21, 2018
  • Young woman affected by depression

    If You Have PTSD You Were Likely Abused as a Child

    Jun 19, 2018
  • Obese dog on a leash

    Obese Dogs Can Help Us Better Understand How Obesity Works

    Jun 18, 2018
  • Our Brains Are Craving Combinations of Fats and Carbs (Study)

    Jun 15, 2018
  • Hungry bird with beck open

    Scientists Explain Why We Get ‘Hangry’

    Jun 13, 2018

Categories

  • Business
  • Entertainment
  • Health
  • National News
  • Nature
  • Provo
  • Salt Lake News
  • Science
  • Sports
  • State News
  • Tech & Science
  • Technology
  • Uncategorized
  • West Jordan
  • West Valley City
  • World

Copyright © 2022 utahpeoplespost.com

About · Privacy Policy · Terms of Use · Site Map · Contact